Navigation Links
QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
Date:9/5/2011

GERMANTOWN, Maryland, September 6, 2011 /PRNewswire/ --

- QIAGEN assay for JAK2 V617F mutation aims to identify patients more likely to respond to Lilly's 'JAK2 inhibitor' and to monitor responses to therapy

- Lilly will co-develop companion diagnostic

- QIAGEN's exclusive access to JAK2 biomarker underpins potential future expansion with additional Pharma compounds targeting gene

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

Lilly's proprietary compound, called a JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.

Under the terms of the agreement, QIAGEN will develop a new companion diagnostic test that will provide both qualitative and quantitative results for JAK2 V617F. The assay is intended to identify patients most likely to benefit from treatment with inhibitors of the pathway. The scope of the partnership includes development and use of the QIAGEN JAK2 assay during clinical trials and also covers manufacturing and joint commercialization of the diagnostic product in parallel with the Lilly compound.

QIAGEN gained exclusive access to the JAK2 biomarker through an agreement with Ipsogen, a French company that is a pioneer in profiling and biomarkers for leukemia and other blood cancers. In June, QIAGEN announced a proposal to fully acquire Ipsogen through a process that is under way. The JAK2 pathway is considered to bring high value to drug development in terms of defining and
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
2. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
3. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
4. QIAGEN Acquires Exclusive Licence for Key PI3K gene
5. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
6. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
7. Plexus Awarded Development Contract With QIAGEN
8. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
9. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
10. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
11. SciQuest Announces Strategic Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: